Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer
(2002) In Clinical Cancer Research 8(1). p.156-164- Abstract
- Purpose: The purpose of this study was to measure total levels of tissue inhibitor of metalloproteinases (TIMP-1) by ELISA in plasma from blood donors, patients with inflammatory bowel disease (IBD), and patients with cancer and to correlate the results to patient diagnosis. Experimental Design: Total TIMP-1 plasma levels were measured by ELISA in blood samples from two different blood donor populations from IBD patients, and preoperative samples from patients with primary colon cancer (CC), rectal cancer (RC), or breast cancer. Results: There were no significant differences in plasma TIMP-1 levels between healthy donors and 1131) or breast cancer patients, whereas patients with CC or RC had significantly elevated TIMP-1 levels. Total... (More)
- Purpose: The purpose of this study was to measure total levels of tissue inhibitor of metalloproteinases (TIMP-1) by ELISA in plasma from blood donors, patients with inflammatory bowel disease (IBD), and patients with cancer and to correlate the results to patient diagnosis. Experimental Design: Total TIMP-1 plasma levels were measured by ELISA in blood samples from two different blood donor populations from IBD patients, and preoperative samples from patients with primary colon cancer (CC), rectal cancer (RC), or breast cancer. Results: There were no significant differences in plasma TIMP-1 levels between healthy donors and 1131) or breast cancer patients, whereas patients with CC or RC had significantly elevated TIMP-1 levels. Total TIMP-1 levels identified patients with CC with a sensitivity of 63% at 98% specificity, patients with early CC (Dukes' A+B) with a sensitivity of 56% at 98% specificity, and patients with right-sided CC with a sensitivity of 72% at 98% specificity. Combining carcinoembryonic antigen and TIMP-1 measurements increased the sensitivities obtained from TIMP-1 measurements alone. Conclusions: TIMP-1 was significantly elevated in plasma from CC and RC patients, including those with early-stage disease. Sensitivity and specificity were both sufficiently high to consider TIMP-1 as a marker for the early identification of CC patients, in particular, those with right-sided CC. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/344199
- author
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Cancer Research
- volume
- 8
- issue
- 1
- pages
- 156 - 164
- publisher
- American Association for Cancer Research
- external identifiers
-
- wos:000173519700023
- pmid:11801553
- scopus:0036156756
- ISSN
- 1078-0432
- language
- English
- LU publication?
- yes
- id
- 18abbcf2-1f41-401d-9134-944d257e57e9 (old id 344199)
- alternative location
- http://clincancerres.aacrjournals.org/cgi/content/full/8/1/156
- date added to LUP
- 2016-04-01 11:37:31
- date last changed
- 2022-05-14 01:27:50
@article{18abbcf2-1f41-401d-9134-944d257e57e9, abstract = {{Purpose: The purpose of this study was to measure total levels of tissue inhibitor of metalloproteinases (TIMP-1) by ELISA in plasma from blood donors, patients with inflammatory bowel disease (IBD), and patients with cancer and to correlate the results to patient diagnosis. Experimental Design: Total TIMP-1 plasma levels were measured by ELISA in blood samples from two different blood donor populations from IBD patients, and preoperative samples from patients with primary colon cancer (CC), rectal cancer (RC), or breast cancer. Results: There were no significant differences in plasma TIMP-1 levels between healthy donors and 1131) or breast cancer patients, whereas patients with CC or RC had significantly elevated TIMP-1 levels. Total TIMP-1 levels identified patients with CC with a sensitivity of 63% at 98% specificity, patients with early CC (Dukes' A+B) with a sensitivity of 56% at 98% specificity, and patients with right-sided CC with a sensitivity of 72% at 98% specificity. Combining carcinoembryonic antigen and TIMP-1 measurements increased the sensitivities obtained from TIMP-1 measurements alone. Conclusions: TIMP-1 was significantly elevated in plasma from CC and RC patients, including those with early-stage disease. Sensitivity and specificity were both sufficiently high to consider TIMP-1 as a marker for the early identification of CC patients, in particular, those with right-sided CC.}}, author = {{Holten-Andersen, MN and Christensen, IJ and Nielsen, HJ and Stephens, RW and Jensen, V and Nielsen, OH and Sorensen, S and Overgaard, J and Lilja, Hans and Harris, A and Murphy, G and Brunner, N}}, issn = {{1078-0432}}, language = {{eng}}, number = {{1}}, pages = {{156--164}}, publisher = {{American Association for Cancer Research}}, series = {{Clinical Cancer Research}}, title = {{Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer}}, url = {{http://clincancerres.aacrjournals.org/cgi/content/full/8/1/156}}, volume = {{8}}, year = {{2002}}, }